Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary target.
Read More
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Read More
Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Read More
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat patients with pulmonary arterial hypertension, a life-threatening condition involving abnormally high blood pressure in the arteries of the lungs.
Read More
Three new specialised treatments are now to be made available on the NHS for patients in England after being initially rejected for funding back in December, NHS England has announced.
Read More
European regulators are advising that doctors can continue prescribing Actelion’s Uptravi for pulmonary arterial hypertension while an investigation into its safety is completed.
Read More
Johnson & Johnson and Actelion have announced a $30 billion merger that will see the latter’s R&D unit spun out into a separate business, ending months of speculation.
Read More
Actelion has suffered a setback in its quest to expand the uses of Tracleer follow-up Opsumit, after a study assessing the drug in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger Syndrome failed to meet its primary goal.
Read More
Johnson & Johnson has bowed out of a potential merger with Actelion, opening up the field for an unconfirmed contender widely believed to be French drugmaker Sanofi.
Read More
EU regulators have issued a green light for Actelion’s Uptravi, offering a new treatment option to patients with pulmonary arterial hypertension.
Read More
